Supernus to Announce Third Quarter 2021 Financial Results and Host Conference Call on November 3, 2021
October 27, 2021 17:42 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Holly Robinson Peete Partners with Supernus to Raise Awareness During ADHD Awareness Month
October 20, 2021 08:00 ET
|
Supernus Pharmaceuticals, Inc.
Peete and her daughter Ryan join forces to amplify the conversation around Attention-deficit/Hyperactivity disorder (ADHD) and neurodiversityNearly one-in-ten – or 6.1 million children and adolescents...
Supernus Pharmaceuticals to Acquire Adamas Pharmaceuticals Strengthening its CNS Product Portfolio
October 11, 2021 06:30 ET
|
Supernus Pharmaceuticals, Inc.
Acquisition of two marketed products diversifies and accelerates revenue and cash flowExpected to be significantly accretive in 2022Potential synergies of $60 million to $80 million in year one due to...
Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
September 02, 2021 18:45 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Participate in Upcoming September Investor Conferences
September 02, 2021 09:00 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces Second Quarter 2021 Financial Results
August 04, 2021 16:09 ET
|
Supernus Pharmaceuticals, Inc.
Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021Qelbree sNDA for adult ADHD submitted to the...
Supernus to Host Second Quarter 2021 Financial Results Conference Call
July 22, 2021 16:37 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., July 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus to Present at Jefferies Virtual Healthcare Conference
May 25, 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age
May 24, 2021 08:30 ET
|
Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of...
Supernus Announces First Quarter 2021 Financial Results
May 05, 2021 16:01 ET
|
Supernus Pharmaceuticals, Inc.
First quarter 2021 total revenues of $130.9 million, a 38% increase compared to 2020Qelbree™ approved by FDA for pediatric ADHD and on track for a U.S. launch in Q2 2021Qelbree sNDA submission for...